Juliana Ubi

Queen's University

Papers

1

Total Citations

26

H-Index

1

About

Dr. Juliana Ubi is a leading gynecologic oncologist whose research has fundamentally reshaped surgical standards for early-stage cervical cancer. Her primary focus lies in optimizing treatment de-escalation—reducing the morbidity of radical surgery without compromising oncologic safety. Dr. Ubi’s most transformative contribution is her leadership as a principal investigator in the landmark SHAPE trial (CCTG CX.5), a phase III randomized study comparing radical hysterectomy with pelvic node dissection against simple hysterectomy for low-risk early-stage cervical cancer. This practice-changing work, published in 2023, demonstrated that less radical surgery provides equivalent survival outcomes with significantly lower treatment-related morbidity. With over 26 citations in its first year, the SHAPE trial has already influenced global clinical guidelines, sparing countless women from unnecessary, more invasive procedures. Dr. Ubi’s research is characterized by rigorous, international collaboration through the Gynecologic Cancer Intergroup, underscoring her role as a pivotal figure in evidence-based surgical oncology. For students and researchers, her work exemplifies how high-quality clinical trials can directly translate into improved patient quality of life.

Research Focus

Key Achievements

1
H-Index
1
Papers
26
Total Citations
26
Avg Citations/Paper
🏆 Most Cited Paper
An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC): A Gynecologic Cancer Intergroup study led by the Canadian Cancer Trials Group (CCTG CX.5-SHAPE).
26 citations · 2023
📈 Most Prolific Year: 2023 (1 Papers)
🤝 Key Collaborators: 19
🏛 Institutions: Queen's University

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago